{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:45:05Z","timestamp":1762530305614,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.adro.2022.100940","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T02:27:13Z","timestamp":1646792833000},"page":"100940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence"],"prefix":"10.1016","volume":"7","author":[{"given":"Tugce","family":"Kutuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Daniel","family":"Grass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solmaz","family":"Sahebjam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungjune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Penagaricano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiang-Hsuan Michael","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Etame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2022.100940_bib0001","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Radiation Therapy Oncology Group Study. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0002","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","article-title":"Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0003","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","article-title":"Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group","volume":"21","author":"Hoang-Xuan","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0004","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0005","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0006","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0007","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jocn.2012.04.001","article-title":"A single centre study of the treatment of relapsed primary central nervous system lymphoma (PCNSL) with single agent temozolomide","volume":"19","author":"Wong","year":"2012","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.adro.2022.100940_bib0008","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0608-3","article-title":"Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma","volume":"105","author":"del Rio","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.adro.2022.100940_bib0009","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdq548","article-title":"Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy","volume":"22","author":"Khimani","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0010","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/neuonc\/now033","article-title":"Primary CNS lymphoma at first relapse\/progression: Characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemercier","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0011","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2011-03-321349","article-title":"How I treat primary CNS lymphoma","volume":"118","author":"Ferreri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.adro.2022.100940_bib0012","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","article-title":"Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Nabors","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.adro.2022.100940_bib0013","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.adro.2022.100940_bib0014","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.adro.2022.100940_bib0015","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","article-title":"The role of autologous stem cell transplantation in primary central nervous system lymphoma","volume":"127","author":"Ferreri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.adro.2022.100940_bib0016","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.adro.2022.100940_bib0017","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","article-title":"Treatment for primary CNS lymphoma: The next step","volume":"18","author":"Abrey","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0018","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.1998.16.3.859","article-title":"Long-term survival in primary CNS lymphoma","volume":"16","author":"Abrey","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0019","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","article-title":"Delayed neurotoxicity in primary central nervous system lymphoma","volume":"62","author":"Omuro","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.adro.2022.100940_bib0020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2002.20.1.231","article-title":"Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD\/BVAM regimen followed by two different radiotherapy treatments","volume":"20","author":"Bessell","year":"2002","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.adro.2022.100940_bib0021","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1200\/JCO.2020.38.15_suppl.2501","article-title":"Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL)","volume":"38","author":"Omuro","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.100940_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncr.11035","article-title":"Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation","volume":"97","author":"Shibamoto","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2022.100940_bib0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jrr\/rrv085","article-title":"Partial-brain radiotherapy for primary central nervous system lymphoma: Multi-institutional experience","volume":"57","author":"Iwabuchi","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.adro.2022.100940_bib0025","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ncl.2007.07.001","article-title":"Primary central nervous system lymphoma","volume":"25","author":"Mohile","year":"2007","journal-title":"Neurol Clin"},{"issue":"15 suppl","key":"10.1016\/j.adro.2022.100940_bib0026","article-title":"Patterns of recurrence in primary central nervous system lymphoma: Mechanistic inferences","volume":"34","author":"Ambady","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0027","first-page":"422","article-title":"Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: Imaging analysis of the ANOCEF-GOELAMS prospective randomized trial","volume":"19","author":"Tabouret","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0028","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.ejrad.2011.05.028","article-title":"MRI patterns in recurrence of primary CNS lymphoma in immunocompetent patients","volume":"81","author":"Schulte-Altedorneburg","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.adro.2022.100940_bib0029","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.adro.2018.07.001","article-title":"Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy","volume":"3","author":"Sheu","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0030","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0031","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0032","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/01.STR.0000150668.58689.f2","article-title":"Anatomical mapping of white matter hyperintensities (WMH): Exploring the relationships between periventricular WMH, deep WMH, and total WMH burden","volume":"36","author":"DeCarli","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.adro.2022.100940_bib0033","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12987-017-0064-3","article-title":"Patterns of relapse in primary central nervous system lymphoma: Inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease","volume":"14","author":"Ambady","year":"2017","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.adro.2022.100940_bib0034","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11912-018-0706-x","article-title":"The utility of liquid biopsy in central nervous system malignancies","volume":"20","author":"Nevel","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.adro.2022.100940_bib0035","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1212\/01.WNL.0000034256.20173.EA","article-title":"Primary CNS lymphoma: A whole-brain disease?","volume":"59","author":"Lai","year":"2002","journal-title":"Neurology"},{"issue":"15 suppl","key":"10.1016\/j.adro.2022.100940_bib0036","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2020.38.15_suppl.2500","article-title":"Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant and adjuvant temozolomide in patients with newly diagnosed primary central nervous system lymphoma: JCOG1114C","volume":"38","author":"Mishima","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0037","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): A randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0038","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","article-title":"Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment","volume":"101","author":"Rubenstein","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.adro.2022.100940_bib0039","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.100940_bib0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/EDBK_242547","article-title":"Evolving treatments for primary central nervous system lymphoma","volume":"39","author":"Ferreri","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.adro.2022.100940_bib0041","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.biopsych.2008.03.024","article-title":"Classification of white matter lesions on magnetic resonance imaging in elderly persons","volume":"64","author":"Kim","year":"2008","journal-title":"Biol Psychiatry"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:40:06Z","timestamp":1762530006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109422000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2452109422000471"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2022.100940","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2022.100940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100940"}}